Effect of allopurinol on diabetic nephropathy

Phase 3

Recruiting

• Conditions: Diabetic nephropathy.; Drug or chemical induced diabetes mellitus with diabetic nephropathy; E09.21

• Registration Number: IRCT20200117046158N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

24-hour urine protein greater than 150mg / dl
Uric acid between 6 and 15
Informed patient satisfaction
The severity of diabetic nephropathy is similar in both groups
Passive urine sedimentation

Exclusion Criteria

Patients treated with allopurinol
Patients with significant renal failure (Cr> 3 mg / dl) or (GFR <25cc / min)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum uric acid level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.;GFR (Glomerular filtration rate). Timepoint: After 3 and 6 months after starting the study. Method of measurement: Formula.;24-hour urine protein content. Timepoint: After 3 and 6 months after starting the study. Method of measurement: 24-hour urine test.;Serum creatinine level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.;Serum urea level. Timepoint: After 3 and 6 months after starting the study. Method of measurement: Test.